Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Eli Lilly Product Tirzepatide Has Impressive Clinical Trial Results Treating MASH

Eli Lilly in the NEWS Eli Lilly and Company ( LLY ) announced detailed results from the SYNERGY-NASH phase 2 study having 190 patients with or without type 2 diabetes to evaluate the investigational use of tirzepatide in adults with...

June 10, 2024

RegenxBio Announced Completion of a Successful Pre-BLA Meeting with the FDA for RGX-121 for Mucopolysaccharidosis Type II

RegenxBio Today RegenxBio ( RGNX ) announced it completed a successful Pre-Biologics License Application ( BLA ) meeting with the FDA for the RGX-121 treatment of Mucopolysaccharidosis Type II ( MPS II ). The FDA continues to be aligned with...

June 18, 2024

Altimmune Important Upcoming Presentations

Altimmune Today, June 18, 2024, Altimmune ( ALT ) announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s ( ADA ) 84thScientific Sessions, to...

June 18, 2024

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Gilead Sciences' Lenacapavir Demonstrated 100% Efficacy in Preventing HIV Gilead Sciences, Inc. ( GILD ) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor,...

June 20, 2024

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients

Sarepta Therapeutics in the NEWS On June 20, 2024, Sarepta Therapeutics ( SRPT ) announced that the U. S. FDA has approved an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD)...

June 21, 2024

Alnylam Pharmaceuticals: Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran

Alnylam Pharamceuticals Announcement June 24, 2024, Alnylam Pharmaceuticals ( ALNY ) announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy ( ATTR-CM )....

June 24, 2024

Advanced Micro Devices to Buy the Largest Private AI Lab in Europe

Advanced Micro Devices in the NEWS Advanced Micro Devices ( AMD ) today announced the signing of a definitive agreement to acquire Silo AI, the largest private AI lab in Europe, in an all-cash transaction valued at approximately $665 million. The...

July 10, 2024

Illumina Acquired Fluent BioSciences to Accelerate Single-Cell Analysis and Discovery to a Broader Customer Base

Illumina Inc The latest take over by Illumina, Inc. ( ILMN ) has been a company with advanced technology known as Fluent BioSciences , a developer of emerging and highly differentiated single-cell technology. From Illumina Inc Informing the biotech...

July 10, 2024

Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics in the NEWS On July 15, 2024, Lexeo Therapeutics ( LXEO ) announced positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across both the Lexeo SUNRISE-FA Phase 1/2 clinical trial ( NCT05445323 )...

July 16, 2024

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

Akero Therapeutics Q2 and Business Update Akero Therapeutics ( AKRO ) reported second-quarter financial results for the period ending June 30, 2024, and provided business updates. From Akero Therapeutics Andrew Cheng, president and CEO said, “The second quarter of 2024...

August 9, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024